AMERISOURCEBERGEN
17.11.2022 14:31:38 CET | Business Wire | Press release
Alliance Healthcare, a part of global healthcare company AmerisourceBergen and a leading wholesaler of pharmaceutical products in Europe, and GIRP, the European Healthcare Distribution Association, convened policymakers and leaders across the healthcare and pharmaceutical industries today to discuss antimicrobial resistance (AMR), examine current response efforts and explore opportunities to collaborate on initiatives to combat the global public health issue.
The inaugural event featured remarks from members of the European Parliament, European Commission and organizations spearheading AMR response efforts, as well as panel discussions led by healthcare and pharmaceutical executives. Panelists and speakers covered a variety of topics, including how public policy can advance response efforts, strategies to increase awareness of AMR, actions healthcare providers are taking to combat resistance, and public-private partnerships to support the development of new antimicrobials. Professor Dame Sally Davies, UK Special Envoy on AMR and member of the UN Global Leaders Group on AMR, delivered a keynote address focused on mobilizing international efforts and driving a global response.
AMR, which occurs when a microorganism (bacteria, virus, fungi, parasite) develops the ability to resist the effects of a drug, is a significant global public health threat. The World Health Organization (WHO), U.S. Government and European Commission each have initiated action plans against AMR.
“Addressing an issue as complex and far-reaching as AMR requires public-private collaboration and coordination across multiple sectors,” said Gianluigi Tassone, President of Alliance Healthcare. “By hosting this event, we sought to bring together policymakers, leaders across the healthcare supply chain and those at the forefront of international response efforts to discuss current approaches, share best practices and identify opportunities in which we can work together to help address this issue.”
“As the EU outlined in its action plan, there is an urgent need for multi-sector collaboration, innovation and policy action to tackle AMR,” said Monika Derecque-Pois, Director General of GIRP. “While this event serves as an important step in bringing together leaders across different industries, it’s equally important we continue these conversations and build on the potential solutions discussed today to help drive meaningful, sustained change.”
During the provider-focused panel, leaders from the European Hospital and Healthcare Federation, Standing Committee of European Doctors, European Association of Hospital Pharmacists and Boots UK offered perspective on how healthcare systems across Europe are prepared to manage AMR. The panelists spoke to the actions needed to combat resistance, including infection prevention and control measures, and initiatives underway to educate patients on AMR. For example, Alphega Pharmacy, a pan-European network of independent pharmacists and a part of Alliance Healthcare, launched a campaign to drive awareness of AMR and provide patients with additional counseling and education on proper use of antibiotics.
Representatives from the AMR Action Fund, a public-private partnership investing in biotech companies that are developing antibiotics, and BEAM Alliance, a coalition of small and medium-sized biopharma companies in Europe involved in developing products to combat AMR, discussed current industry priorities, including innovative approaches to support the research and development of new antibiotics and sustainable models to improve access to new antibiotics, diagnostics and vaccines globally.
“AMR is a silent pandemic. No one player can solve it on their own – it demands a coordinated approach,” said Dame Sally. “By collaborating across sectors and countries, we can innovate to secure the future of modern medicine so that treatments can be used sustainably by all who need them.”
About AmerisourceBergen
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies, and providers, we create unparalleled access, efficiency, and reliability for human and animal health. Our more than 43,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at https://amerisourcebergen.com/.
European Healthcare Distribution Association (GIRP)
GIRP, the European Healthcare Distribution Association, is the umbrella organisation for full-service healthcare distributors in Europe. It represents the national associations of over 750 pharmaceutical wholesalers serving 34 European countries, as well as major international and pan-European healthcare distribution companies. GIRP members employ over 140,000 people and distribute around 15 billion packs of medicines as well as a wide range of healthcare products per year. As the vital link in healthcare, they are committed to developing and providing innovative and efficient healthcare products and services to improve health and wellbeing of patients across Europe. Learn more at girp.eu.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005239/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bial Achieves Key Milestone in Phase 2b ACTIVATE Study of BIA 28-6156 in GBA1-Associated Parkinson’s Disease27.1.2026 12:00:00 CET | Press release
75% of patients have completed the Week 78 Last Study VisitTopline results expected in mid-2026 Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that 75% of patients currently enrolled in its ongoing Phase 2b clinical study ACTIVATE (ClinicalTrials.gov identifier: NCT05819359) have completed the double-blind treatment period through week 78. This operational milestone represents a significant step toward the completion of the ACTIVATE study, which is evaluating the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156 in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). The date of the Last Patient, Last Visit (LPLV) is anticipated in April 2026, with topline results on track to be released in mid-2026. “We look forward to presenting data from our Phase 2b study. BIA 28-6156 is the leading asset in GBA-PD, and clinical out
Libraesva and Cyber Guru Announce Strategic Combination to Create a Leading European Human-Centric Cybersecurity Provider27.1.2026 11:00:00 CET | Press release
The combination of two Italian cybersecurity leaders with strong international footprints creates a unique European player delivering an integrated portfolio of Email Security and Security Awareness Training to reduce human cyber risk end-to-end. Cyber Guru and Libraesva today announced a strategic combination that brings together two highly complementary Italian cybersecurity companies to form a new European leader in human-centric cyber protection. The combined group will offer organisations an integrated approach to defending against email-based threats, social engineering, and human-targeted attacks, integrating advanced technology with behavioural resilience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127531600/en/ Cyber threats are evolving rapidly, with attackers focusing less on infrastructure and more on the weak link in security – human behaviour. Phishing, business email compromise, smishing, QR-code attack
Europe’s First Meteorological Infrared Sounder Reveals the Atmosphere in 3D27.1.2026 10:30:00 CET | Press release
The first images from Europe’s pioneering meteorological infrared sounder were unveiled today at the EU Space Conference in Brussels, marking a major advance in the ability to monitor how the atmosphere evolves before and during severe weather. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127490399/en/ Full Earth disc image from the MTG-S Infrared Sounder showing a surface-temperature-sensitive channel, captured between 12:45 and 15:30 UTC on 15 November 2025. The image distinguishes land and sea surface temperatures as well as cloud-top temperatures, highlighting cloud structures and weather systems. Hot desert regions appear in red, while cold cloud tops are shown in blue. © Image: Data acquired on 15 November 2025 and processed by industrial partners Thales and OHB under the supervision of EUMETSAT and ESA. Visual produced by EUMETSAT. The images were captured by the Infrared Sounder (IRS) flying aboard Meteosat Thir
Clearwater Analytics Embeds AI into Beacon Risk Platform to Accelerate Model Validation and Exposure Analysis27.1.2026 10:00:00 CET | Press release
Production-grade AI transforms quantitative workflows—from scenario analysis to tail risk modeling—inside investment risk operations engine Clearwater Analytics(NYSE: CWAN), the most comprehensive technology platform for investment management, today announced breakthrough embedded agentic AI capabilities within Beacon by CWAN, its enterprise risk and quantitative analytics platform, enabling risk teams to accelerate model validation, exposure analysis, and decision-making. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126906084/en/ As regulatory scrutiny intensifies and portfolio complexity reaches unprecedented levels, traditional risk platforms are failing institutional investors when they need answers most. Built specifically for quantitative developers and risk professionals managing complex institutional portfolios, CWAN’s embedded AI operates within Beacon’s calculation engine itself, training the agents our client
Seasoned European Software Executive David Coste to Join Battery Ventures27.1.2026 09:00:00 CET | Press release
Coste, a longtime leader at pan-European ERP provider Forterro, will be a Battery executive-in-residence Battery Ventures, the global, technology-focused investment firm, announced it has hired former Forterro executive David Coste as an executive-in-residence based in its London office, effective next month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127122321/en/ David Coste, a former Forterro executive who begins a new executive-in-residence role with global investment firm Battery Ventures in London in February. At Battery, Coste will work closely with Battery Partner Zak Ewen and General Partner Morad Elhafed, among others, to help source and evaluate business-technology investments throughout Europe. Battery first opened its London office in 2016 and, since 2005, has completed more than 150 transactions across 13 countries including the U.K., Germany, France, the Netherlands, Belgium, Switzerland, Sweden and Nor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom